Baxter International Inc.’s Stock Price Soars to $37.12, Registers a Robust 3.77% Growth

Baxter International Inc. (BAX)

37.12 USD +1.35 (+3.77%) Volume: 5.03M

Baxter International Inc.’s stock price stands at 37.12 USD, showcasing a positive surge of +3.77% in the recent trading session with a trading volume of 5.03M. Despite a slight dip of -3.98% YTD, BAX continues to be a key player in the market.

Latest developments on Baxter International Inc.

Following the closure of a Baxter International plant and the aftermath of Hurricane Helene, hospitals across the US are facing a shortage of IV fluids and dialysis solutions. The American Hospital Association has called on the White House for assistance in easing the shortage, while Virginia hospitals are assessing the impact of the supply chain constraints. Despite the challenges, Baxter International (NYSE:BAX) saw a 3.3% increase in its stock shares, with Handelsbanken Fonder AB purchasing additional shares. In response to the crisis, rival company Fresenius is working to increase production to help alleviate the strain on the healthcare system. As the IV fluid manufacturer resumes shipments to hospitals and dialysis centers, Irving-Based Vizient has shared conservation strategies to manage potential supply disruptions. Despite the ongoing challenges, Baxter shares remain steady with a $40 target price amid updates on the IV fluid situation.

Baxter International Inc. on Smartkarma

Analysts at Baptista Research on Smartkarma are bullish on Baxter International, a company specializing in kidney care. In their report titled “Baxter International Inc.: An Insight Into The Market Share and Competitiveness in Kidney Care! – Major Drivers,” they highlighted the company’s second quarter 2024 earnings which exceeded expectations. This positive outcome was attributed to Baxter’s strategic overhaul and operational enhancements, leading to an uplifting revision in the full-year financial forecast.

Furthermore, Baptista Research‘s report “Baxter International: Driving Revenue with New Innovations and Competitive Conversions! – Major Drivers” emphasized Baxter International‘s first quarter 2024 earnings report, where the company exceeded its guidance with 2% growth on a reported basis and 3% at constant currency rates. The analysts attributed this performance to strong demand and favorable pricing for Baxter’s products, showcasing the benefits of the company’s recent strategic transformation. Overall, the analysts on Smartkarma are optimistic about Baxter International‘s future prospects.

A look at Baxter International Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Baxter International has a strong outlook for its dividend and momentum. With a score of 5 for dividend, investors can expect consistent and reliable returns in the form of dividends. Additionally, the company scored a 4 in momentum, indicating a positive trend in the stock price that may continue in the future. However, Baxter International scored lower in growth and resilience, with scores of 2 for both factors. This suggests that the company may face challenges in expanding its business and could be vulnerable to market fluctuations.

Baxter International Inc. focuses on developing and manufacturing products for various medical conditions, making it a key player in the healthcare industry. While the company’s strong dividend and momentum scores indicate a promising future, the lower scores in growth and resilience highlight areas that may need attention. Investors should consider these factors when evaluating the long-term potential of Baxter International as they weigh the company’s stability and growth prospects.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma